SG11202110579WA - Methods of reducing large granular lymphocyte and natural killer cell levels - Google Patents

Methods of reducing large granular lymphocyte and natural killer cell levels

Info

Publication number
SG11202110579WA
SG11202110579WA SG11202110579WA SG11202110579WA SG11202110579WA SG 11202110579W A SG11202110579W A SG 11202110579WA SG 11202110579W A SG11202110579W A SG 11202110579WA SG 11202110579W A SG11202110579W A SG 11202110579WA SG 11202110579W A SG11202110579W A SG 11202110579WA
Authority
SG
Singapore
Prior art keywords
methods
natural killer
killer cell
large granular
cell levels
Prior art date
Application number
SG11202110579WA
Other languages
English (en)
Inventor
Nenad Tomasevic
Ruo Shi Shi
Arun Kashyap
Original Assignee
Dren Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dren Bio Inc filed Critical Dren Bio Inc
Publication of SG11202110579WA publication Critical patent/SG11202110579WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202110579WA 2019-03-29 2020-03-26 Methods of reducing large granular lymphocyte and natural killer cell levels SG11202110579WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962826660P 2019-03-29 2019-03-29
US202062982578P 2020-02-27 2020-02-27
PCT/US2020/025012 WO2020205440A1 (fr) 2019-03-29 2020-03-26 Méthodes de réduction des niveaux de grands lymphocytes granuleux et de cellules tueuses naturelles

Publications (1)

Publication Number Publication Date
SG11202110579WA true SG11202110579WA (en) 2021-10-28

Family

ID=72666908

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110579WA SG11202110579WA (en) 2019-03-29 2020-03-26 Methods of reducing large granular lymphocyte and natural killer cell levels

Country Status (10)

Country Link
US (1) US20220185895A1 (fr)
EP (1) EP3946455A4 (fr)
JP (1) JP2022528000A (fr)
KR (1) KR20220032513A (fr)
CN (1) CN113874035A (fr)
AU (1) AU2020251987A1 (fr)
CA (1) CA3135422A1 (fr)
IL (1) IL286720A (fr)
SG (1) SG11202110579WA (fr)
WO (1) WO2020205440A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023003685A (es) 2020-09-30 2023-06-02 Dren Bio Inc Anticuerpos anti-cd94 y metodos de uso de los mismos.
JP2023549559A (ja) * 2020-11-18 2023-11-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ナチュラルキラー細胞に対する枯渇モノクローナル抗体
WO2023183926A1 (fr) * 2022-03-25 2023-09-28 Dren Bio, Inc. Anticorps anti-cd94 et procédés d'utilisation associés

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2591059C (fr) * 2004-12-28 2018-11-06 Innate Pharma Anticorps monoclonaux contre le nkg2a
US9447185B2 (en) * 2005-10-14 2016-09-20 Innate Pharma, S.A. Compositions and methods for treating proliferative disorders
NO346945B1 (no) * 2006-06-30 2023-03-13 Novo Nordisk As Anti-NKG2A-antistoffer og anvendelser derav
BRPI0908508A2 (pt) * 2008-01-24 2016-03-22 Novo Nordisk As anticorpo monoclonal nkg2a anti-humano humanizado
AU2012268939B2 (en) * 2011-06-17 2017-05-04 Novo Nordisk A/S Selective elimination of erosive cells
EP3193929B1 (fr) * 2014-09-16 2019-06-12 Innate Pharma Régimes de traitement utilisant des anticorps anti-nkg2a

Also Published As

Publication number Publication date
AU2020251987A1 (en) 2021-10-28
IL286720A (en) 2021-10-31
KR20220032513A (ko) 2022-03-15
CA3135422A1 (fr) 2020-10-08
CN113874035A (zh) 2021-12-31
US20220185895A1 (en) 2022-06-16
JP2022528000A (ja) 2022-06-07
EP3946455A4 (fr) 2022-12-21
WO2020205440A1 (fr) 2020-10-08
EP3946455A1 (fr) 2022-02-09

Similar Documents

Publication Publication Date Title
IL286720A (en) Methods to reduce the levels of large-granular lymphocytes and natural killer cells
IL273979A (en) Methods for the production of adapted natural killer cells and methods of use
IL285543A (en) Natural killer cells modified for immunotherapy
HK1252582B (zh) 具有增强的細胞毒性的修飾的天然殺傷細胞和天然殺傷細胞系
IL269553A (en) Truncated chimeric NKG2D receptors and their uses in immunotherapy with natural killer cells
IL285039A (en) Preparations and methods for stimulating natural killer cells
EP3980450A4 (fr) Combinaisons de cellules tueuses naturelles modifiées et de cellules t modifiées pour une immunothérapie
EP3616100A4 (fr) Placement et routage de cellules en utilisant des effets de contrainte dépendant de la topologie au niveau de la cellule
EP3850004A4 (fr) Compositions de cellules tueuses naturelles et méthodes d'immunothérapie pour traiter des tumeurs
EP3686274A4 (fr) Procédé pour la production de cellules tueuses naturelles et son utilisation
SG11202106565WA (en) Media and methods for differentiating natural killer cells
IL291622A (en) Compositions comprising regulatory t cells and methods of making and using them
GB202001194D0 (en) Methods of cell selection and modifying cell metabolism
IL286620A (en) T-cell receptors and methods of using them
EP4048296A4 (fr) Procédé de production de cellules tueuses naturelles et compositions associées
SG11202101455TA (en) Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
GB201704953D0 (en) Natural killer cells
IL290946A (en) nef-containing t cells and methods for their production
GB201810486D0 (en) Natural killer cells
EP3570824A4 (fr) Compositions et procédés de régulation de l'activation et de la fonction de cellules tueuses naturelles
EP4065691A4 (fr) Immunothérapie par cellules tueuses naturelles pour le traitement du glioblastome et d'autres cancers
IL276374A (en) Natural killer cells are resistant to transforming growth factor beta
EP3802797A4 (fr) Procédés de fabrication de cellules tueuses naturelles et leurs utilisations
KR102504039B9 (ko) 자연살해세포 증식에 효과적인 배양 방법 및 이의 용도
EP3790891A4 (fr) Produits à base de de cellules tueuses naturelles et procédés